NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH

Active Not RecruitingN/A

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Conditions: Antidiuretic Hormone, Inappropriate Secretion

Interventions: Tolvaptan (SAMSCA)

Countries: Japan

The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Subjects with a definite diagnosis of SIADH in reference to "Diagnostic and Treatment Manual of the Hypersecretion of Vasopressin (SIADH), Revised in 2018"

Exclusion Criteria:

\-

Locations (1)

Osaka, Osaka, Japan